FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317863026> ?p ?o ?g. }

• W4317863026 endingPage "10" @default.
• W4317863026 startingPage "10" @default.
• W4317863026 abstract "10 Background: Interest in organ preservation (OP) strategies for rectal cancer (RC) patients persists. The efficacy of long course chemoradiation (LCRT) vs. short course radiation therapy (SCRT) relative to OP is unknown. We compared OP rates between SCRT and LCRT total neoadjuvant therapy (TNT) strategies. Methods: During the COVID-19 pandemic we established an institutional SCRT mandate with no exceptions. For comparison, we identified RC patients treated with LCRT immediately before and after the mandate period. After completion of TNT, patients were restaged by clinical exam, endoscopy, and MRI. A watch and wait (WW) approach was recommended for patients with a clinical complete response (cCR), defined by the MSK regression schema. Total mesorectal excision (TME) was recommended for non-cCR patients. OP was defined as alive, TME-free, and with no evidence of disease in the pelvis. We performed survival analysis for: local regrowth rate, OP, disease-free survival (DFS), and overall survival (OS). Results: We identified 563 consecutive patients with RC treated with TNT, of whom 231 were excluded due to either metastatic disease, synchronous/metachronous malignancies, or non-adenocarcinoma histology (Jan. 2018-Jan. 2021). Patient and tumor characteristics were similar in the LCRT (n = 256) and SCRT (n = 76) cohorts. No significant differences in high-risk features were noted. Most patients had clinical stage III disease (82% in LCRT vs. 83% in SCRT). Induction chemotherapy followed by consolidative radiation was the most common treatment order (78% (LCRT) vs. 70% (SCRT)). The median interval from end of TNT to clinical restaging was 8 weeks (LCRT) and 9 weeks (SCRT). The cCR rate was 46% in both cohorts. The cCR rate was numerically higher in patients treated with radiation first, as compared to chemotherapy first (53% vs. 44% (LCRT) and 52% vs. 43% (SCRT)). Among patients with a cCR, the likelihood of WW management was similar (98% (LCRT) vs. 94% (SCRT)). From start of TNT, the median follow-up was 32 and 28 months respectively for LCRT and SCRT. The 2-year OS (95% vs. 92%), DFS (78% vs 70%), and distant recurrence (20% vs. 21%) rates were similar. Among all patients, the 2-year OP rate was 40% (95% CI 35-47%) for LCRT and 29% (95% CI 20-42%) with SCRT. In those patients managed by WW, the 2-year local regrowth rate was 20% (95% CI 12-27%) with LCRT vs. 36% (95% CI 16-52%) with SCRT. Conclusions: In this nonrandomized comparison, while cCR rates were similar, we observed a numerically higher OP rate with LCRT-TNT than with SCRT-TNT. The ongoing ACO/ARO/AIO-18.1 trial, hypothesizing that LCRT-TNT will increase OP rates relative to SCRT-TNT, should definitively answer this question." @default.
• W4317863026 created "2023-01-25" @default.
• W4317863026 creator A5000903330 @default.
• W4317863026 creator A5010136395 @default.
• W4317863026 creator A5012783995 @default.
• W4317863026 creator A5013157364 @default.
• W4317863026 creator A5013679800 @default.
• W4317863026 creator A5016694714 @default.
• W4317863026 creator A5017049966 @default.
• W4317863026 creator A5030781113 @default.
• W4317863026 creator A5031539570 @default.
• W4317863026 creator A5034300766 @default.
• W4317863026 creator A5037120205 @default.
• W4317863026 creator A5049301598 @default.
• W4317863026 creator A5051277222 @default.
• W4317863026 creator A5052448371 @default.
• W4317863026 creator A5054605021 @default.
• W4317863026 creator A5059768717 @default.
• W4317863026 creator A5060751046 @default.
• W4317863026 creator A5074971164 @default.
• W4317863026 creator A5079606054 @default.
• W4317863026 creator A5083740899 @default.
• W4317863026 date "2023-02-01" @default.
• W4317863026 modified "2023-10-18" @default.
• W4317863026 title "Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy." @default.
• W4317863026 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.10" @default.
• W4317863026 hasPublicationYear "2023" @default.
• W4317863026 type Work @default.
• W4317863026 citedByCount "1" @default.
• W4317863026 countsByYear W43178630262023 @default.
• W4317863026 crossrefType "journal-article" @default.
• W4317863026 hasAuthorship W4317863026A5000903330 @default.
• W4317863026 hasAuthorship W4317863026A5010136395 @default.
• W4317863026 hasAuthorship W4317863026A5012783995 @default.
• W4317863026 hasAuthorship W4317863026A5013157364 @default.
• W4317863026 hasAuthorship W4317863026A5013679800 @default.
• W4317863026 hasAuthorship W4317863026A5016694714 @default.
• W4317863026 hasAuthorship W4317863026A5017049966 @default.
• W4317863026 hasAuthorship W4317863026A5030781113 @default.
• W4317863026 hasAuthorship W4317863026A5031539570 @default.
• W4317863026 hasAuthorship W4317863026A5034300766 @default.
• W4317863026 hasAuthorship W4317863026A5037120205 @default.
• W4317863026 hasAuthorship W4317863026A5049301598 @default.
• W4317863026 hasAuthorship W4317863026A5051277222 @default.
• W4317863026 hasAuthorship W4317863026A5052448371 @default.
• W4317863026 hasAuthorship W4317863026A5054605021 @default.
• W4317863026 hasAuthorship W4317863026A5059768717 @default.
• W4317863026 hasAuthorship W4317863026A5060751046 @default.
• W4317863026 hasAuthorship W4317863026A5074971164 @default.
• W4317863026 hasAuthorship W4317863026A5079606054 @default.
• W4317863026 hasAuthorship W4317863026A5083740899 @default.
• W4317863026 hasConcept C121608353 @default.
• W4317863026 hasConcept C126322002 @default.
• W4317863026 hasConcept C141071460 @default.
• W4317863026 hasConcept C143998085 @default.
• W4317863026 hasConcept C146357865 @default.
• W4317863026 hasConcept C151730666 @default.
• W4317863026 hasConcept C2777201421 @default.
• W4317863026 hasConcept C2778292576 @default.
• W4317863026 hasConcept C2778424827 @default.
• W4317863026 hasConcept C2779840525 @default.
• W4317863026 hasConcept C509974204 @default.
• W4317863026 hasConcept C526805850 @default.
• W4317863026 hasConcept C530470458 @default.
• W4317863026 hasConcept C71924100 @default.
• W4317863026 hasConcept C86803240 @default.
• W4317863026 hasConceptScore W4317863026C121608353 @default.
• W4317863026 hasConceptScore W4317863026C126322002 @default.
• W4317863026 hasConceptScore W4317863026C141071460 @default.
• W4317863026 hasConceptScore W4317863026C143998085 @default.
• W4317863026 hasConceptScore W4317863026C146357865 @default.
• W4317863026 hasConceptScore W4317863026C151730666 @default.
• W4317863026 hasConceptScore W4317863026C2777201421 @default.
• W4317863026 hasConceptScore W4317863026C2778292576 @default.
• W4317863026 hasConceptScore W4317863026C2778424827 @default.
• W4317863026 hasConceptScore W4317863026C2779840525 @default.
• W4317863026 hasConceptScore W4317863026C509974204 @default.
• W4317863026 hasConceptScore W4317863026C526805850 @default.
• W4317863026 hasConceptScore W4317863026C530470458 @default.
• W4317863026 hasConceptScore W4317863026C71924100 @default.
• W4317863026 hasConceptScore W4317863026C86803240 @default.
• W4317863026 hasFunder F4320332161 @default.
• W4317863026 hasIssue "4_suppl" @default.
• W4317863026 hasLocation W43178630261 @default.
• W4317863026 hasOpenAccess W4317863026 @default.
• W4317863026 hasPrimaryLocation W43178630261 @default.
• W4317863026 hasRelatedWork W2032042555 @default.
• W4317863026 hasRelatedWork W2081586843 @default.
• W4317863026 hasRelatedWork W2362524478 @default.
• W4317863026 hasRelatedWork W2620209048 @default.
• W4317863026 hasRelatedWork W2769770852 @default.
• W4317863026 hasRelatedWork W3031488800 @default.
• W4317863026 hasRelatedWork W3032158305 @default.
• W4317863026 hasRelatedWork W3138000218 @default.
• W4317863026 hasRelatedWork W3160068387 @default.
• W4317863026 hasRelatedWork W3167504304 @default.
• W4317863026 hasVolume "41" @default.
• W4317863026 isParatext "false" @default.

• next